AGAPE ATP CORPORATION (ATPC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 1.32M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | |
| Operating income | -3.14M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.32M | (m) | $-3.14M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $1.51M | (m) | $-3.21M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $1.52M | (m) | $-3.26M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $1.48M | (m) | $-2.81M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $1.45M | (m) | $-2.75M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $1.29M | (m) | $-2.57M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $1.32M | (m) | $-2.57M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $1.35M | (m) | $-2.74M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $1.38M | (m) | $-2.51M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $1.37M | (m) | $-2.42M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $1.43M | (m) | $-2.15M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $1.43M | (m) | $-1.89M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $1.74M | (m) | $-1.77M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $1.83M | (m) | $-1.71M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $1.86M | (m) | $-1.53M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $1.68M | (m) | $-1.51M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $1.22M | (m) | $-1.69M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $1.12M | (m) | $-1.79M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $1.02M | (m) | $-1.86M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $1.32M | (m) | $-1.57M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $2.53M | (m) | $-796.32K | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $3.74M | (m) | $-341.13K | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $3.43M | (m) | $-158.13K | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | $107.77K | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $1.29M | (m) | $-400.42K | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $1.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $1.55M | (m) | $-131.17K | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $1.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $682.79K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $487.00K | (m) | $-234.09K | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |